PURPOSE: Following the introduction of a multimodal approach to diagnosis and treatment, the prognosis of rhabdomyosarcoma (RMS) has markedly improved over the last three decades. However, there are few data on treatment outcomes in Korean patients. MATERIALS AND METHODS: We performed a retrospective analysis of 77 patients with RMS diagnosed and treated at Seoul National University Children's Hospital between 1986 and 2005. RESULTS: The overall 5-year survival and event-free survival rates for all patients were 77% and 59%, respectively. The Intergroup Rhabdomyosarcoma Study clinical grouping and initial response to treatment (20-week response) were important prognostic factors. CONCLUSIONS: The outcome of childhood RMS was closely associated with the initial staging and the initial response to treatment. Modulating therapies according to initial responses and risk factors is critical, and new treatment strategies for high-risk patients are needed.
PURPOSE: Following the introduction of a multimodal approach to diagnosis and treatment, the prognosis of rhabdomyosarcoma (RMS) has markedly improved over the last three decades. However, there are few data on treatment outcomes in Korean patients. MATERIALS AND METHODS: We performed a retrospective analysis of 77 patients with RMS diagnosed and treated at Seoul National University Children's Hospital between 1986 and 2005. RESULTS: The overall 5-year survival and event-free survival rates for all patients were 77% and 59%, respectively. The Intergroup Rhabdomyosarcoma Study clinical grouping and initial response to treatment (20-week response) were important prognostic factors. CONCLUSIONS: The outcome of childhood RMS was closely associated with the initial staging and the initial response to treatment. Modulating therapies according to initial responses and risk factors is critical, and new treatment strategies for high-risk patients are needed.
Authors: Judith A Punyko; Ann C Mertens; K Scott Baker; Kirsten K Ness; Leslie L Robison; James G Gurney Journal: Cancer Date: 2005-04-01 Impact factor: 6.860
Authors: M Carli; R Colombatti; O Oberlin; M Stevens; L Masiero; E Frascella; E Koscielniak; J Treuner; C R Pinkerton Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: E Koscielniak; T H Klingebiel; C Peters; J Hermann; S T Burdach; C Bender-Götze; S T Müller-Weihrich; J Treuner Journal: Bone Marrow Transplant Date: 1997-02 Impact factor: 5.483
Authors: M Carli; R Colombatti; O Oberlin; G Bisogno; J Treuner; E Koscielniak; G Tridello; A Garaventa; R Pinkerton; M Stevens Journal: J Clin Oncol Date: 2004-12-01 Impact factor: 44.544
Authors: H M Maurer; M Beltangady; E A Gehan; W Crist; D Hammond; D M Hays; R Heyn; W Lawrence; W Newton; J Ortega Journal: Cancer Date: 1988-01-15 Impact factor: 6.860
Authors: W Crist; E A Gehan; A H Ragab; P S Dickman; S S Donaldson; C Fryer; D Hammond; D M Hays; J Herrmann; R Heyn Journal: J Clin Oncol Date: 1995-03 Impact factor: 44.544
Authors: F H Kung; S J Desai; J D Dickerman; A M Goorin; M B Harris; S Inoue; J P Krischer; S B Murphy; C B Pratt; S Toledano Journal: J Pediatr Hematol Oncol Date: 1995-08 Impact factor: 1.289